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Edited by Miguel De la RosaAbstract High density lipoproteins (HDL) protect the heart
against ischemia/reperfusion (I/R) injury, and matrix metallo-
proteinase-2 (MMP-2) directly contributes to cardiac contractile
dysfunction after I/R. To investigate the possible involvement of
MMP-2 inhibition in HDL-mediated cardioprotection, isolated
rat hearts underwent 20 min of low-ﬂow ischemia and 30 min
of reperfusion. Plasma-derived and synthetic HDL attenuated
the I/R-induced cardiac MMP-2 activation and release in a
dose-dependent way. The attenuation of I/R-induced MMP-2
activation by HDL correlated with the reduction of post-ische-
mic contractile dysfunction and cardiomyocyte necrosis. These
results indicate prevention of MMP-2 activation as a novel
mechanism for HDL-mediated cardioprotection.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Matrix metalloproteinases (MMPs) are zinc-dependent
endopeptidases involved in the remodeling of extracellular ma-
trix (ECM). They are synthesized and secreted as pro-enzymes
(zymogens), and then activated by proteinases or by non-pro-
teolytic agents that can modify the ‘‘cysteine switch’’ [1].
MMP-2, or gelatinase A, is expressed in the myocardium,
where it is synthesized by ﬁbroblasts and cardiomyocytes [2].
Within the heart, MMP-2 degrades almost all ECM compo-
nents and participates in the long-term cardiac remodeling
which follows a myocardial infarction [2]. Indeed, targeted
deletion or pharmacological inhibition of MMP-2 improves
cardiac activity and survival rate after acute myocardial infarc-Abbreviations: ApoA-I, apolipoprotein A-I; CK, creatine kinase; EC-
M, extracellular matrix; FN, ﬁbronectin; HDL, high density lipopro-
teins; I/R, ischemia/reperfusion; K–H, Krebs–Henseleit; LDL, low
density lipoproteins; LOOH, lipid hydroperoxide; LVDP, left ventric-
ular developed pressure; MMP-2, matrix metalloproteinase 2; ROS,
radical oxygen species; sHDL, synthetic HDL; TnI, troponin I
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has been described; among these, troponin I (TnI) [4], thus
implying MMP-2 as a primary mediator of cardiac dysfunction
following I/R [5].
We have recently demonstrated that plasma-derived or syn-
thetic HDL cause a rapid improvement of post-ischemic car-
diac function in isolated rat hearts undergoing ischemia/
reperfusion (I/R) injury; this cardioprotective eﬀect is dose-
dependent and occurs at HDL concentrations that are nor-
mally found in the plasma of healthy individuals [6,7].
HDL have been shown to inhibit the expression and activa-
tion of MMP-2 and MMP-9 induced by oxidized LDL in
smooth muscle cells and macrophages [8,9]. Moreover, the
infusion of plasma-derived and synthetic HDL prevented
MMP-9 expression in rabbit aortic lesions induced by a com-
bination of cholesterol rich diet and balloon denudation [10].
The aim of the present study was thus to investigate whether
a modulation of MMP-2 expression and/or activation could
contribute to the cardioprotective eﬀect of plasma-derived
and synthetic HDL in isolated hearts undergoing I/R injury.2. Materials and methods
2.1. Experimental protocol
I/R was carried out in isolated rat hearts as previously described
[6,7]. Brieﬂy, hearts were equilibrated with Krebs–Henseleit (K–H)
buﬀer at a ﬂow rate of 15 ml/min for 30 min and underwent a
20 min low-ﬂow ischemia (1 ml/min) followed by 30 min of reperfusion
at the starting ﬂow. Human plasma HDL, low density lipoproteins
(LDL) and synthetic HDL (sHDL) were prepared as previously de-
scribed [6,7], and administered during the 10 min immediately before
ischemia (n = 3 for each treatment group); a separate group of hearts
was similarly treated with an equal volume of saline. Control hearts
(n = 3) were mounted and perfused with K–H buﬀer at the constant
ﬂow rate of 15 ml/min for 80 min. At the end of the experiment, hearts
were snap-frozen in liquid nitrogen and stored at 80 C. Cardiac
homogenates were prepared as described [6] and suspended in PBS
containing AEBSF 2 mM, EDTA 1 mM, Bestatin 130 lM, E-64
14 lM, Leupeptin 1 lM, Aprotinin 0.3 lM (Sigma–Aldrich). After
1 h incubation at 4 C, the homogenates were centrifuged for 20 min
at 20000 · g at 4 C and protein content measured by the BCAmethod
(Pierce).2.2. Zymography and Western blotting for MMP-2
The gelatinolytic activity of cardiac homogenates (40 lg of total pro-
tein) was evaluated by zymography, as previously described [11]. Band
densities were evaluated with a GS-690 Imaging Densitometer and a
Multi-Analyst software (Bio-Rad Laboratories). Aliquots of coro-
nary eﬄuent (10 ml) collected in the ﬁrst 5 min of reperfusion wereblished by Elsevier B.V. All rights reserved.
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transferred on nitrocellulose membranes. Membranes were saturated
with 5% non-fat dried milk at 4 C, and incubated with a mouse mono-
clonal antibody against MMP-2 (Calbiochem) and with an HRP-con-
jugated rabbit anti-mouse antibody (Dakocytomation). Bands were
visualized by enhanced chemiluminescence (Amersham Biosciences).
Each experiment was performed at least three times with diﬀerent heart
preparations.
2.3. Western blotting for ﬁbronectin
Cardiac homogenates (20 lg of total protein) were subjected to
SDS-PAGE (8% acrylamide) under reducing conditions and the sepa-
rated proteins were transferred on nitrocellulose membranes. Mem-
branes were saturated overnight with 5% non-fat dried milk at 4 C,
incubated with a rabbit polyclonal antibody against rat ﬁbronectin
(Sigma–Aldrich) and with an HRP-conjugated goat anti-rabbit anti-
body (Dakocytomation). Bands were visualized by enhanced chemilu-
minescence (Amersham Biosciences). Membranes were then stripped
and reprobed with an antibody against a-actin (Sigma–Aldrich).Fig. 1. Eﬀect of HDL on cardiac MMP-2 content. Panel A:
Representative zymography of homogenates from non-ischemic hearts
(Control) and I/R hearts treated with saline, HDL or LDL (both at
1 mg of protein/ml) during the 10 min immediately before ischemia.
Panel B: Densitometric analysis of total MMP-2 gelatinolytic activity
in cardiac tissue samples. Data are expressed as mean ± SEM, n = 3 for
each group. *P < 0.05 versus saline.2.4. RT-PCR
Total RNA was extracted from cardiac homogenates with Trizol
Reagent (Life Technologies); cDNA was prepared by reverse transcrip-
tion of 1 lg total RNA using the iScript cDNA Synthesis kit (Bio-Rad
Laboratories), and ampliﬁed for 30 cycles with iTaq DNA polymerase
(Bio-Rad laboratories) in a MyCycler (Bio-Rad Laboratories). The
following primers were used: MMP-2 sense 5 0-CCCCTATCTACACC-
TACACCAAGAAC-30, antisense 5 0-CATTCCAGGAGTCTGCGA-
TGAGC-30, producing a 576 bp fragment; GAPDH sense
5 0-ACGACCCCTTCATTGACC-3 0, antisense 5 0-TGCTTCAC-
CACCTTCTTG-3 0, producing a 691 bp fragment. PCR products were
separated by electrophoresis on 1% agarose gel, stained with ethidium
bromide, visualized by ultraviolet irradiation and photographed with
Polaroid ﬁlm. Band densities were evaluated with a GS-690 Imaging
Densitometer and a Multi-Analyst software (Bio-Rad Laboratories).
MMP-2 band intensities were normalized by their GADPH values.2.5. Determination of cardiac lipid hydroperoxides
Aliquots of cardiac homogenates were suspended in PBS containing
5 mM BHT and centrifuged at 4  C for 10 min at 20000 · g. Protein
concentration was measured by the method of Lowry [12]. Lipid
hydroperoxide (LOOH) concentration was estimated by a iodometric
procedure: after incubation with phosphate-buﬀered potassium iodide
(0.12 M) in the dark for 30 min, the conversion of iodide to iodine by
LOOH was measured at 365 nm. Concentrations of LOOH in cardiac
homogenates were calculated by the molar absorption of I3 at 365 nm
(24,600 M1 cm1) and corrected for protein concentration.
2.6. Statistical analysis
Results are reported as mean ± SEM. Diﬀerences among the groups
were evaluated by 1-way ANOVA, with post hoc evaluation by the
Neuman–Keuls test. Statistical signiﬁcance was deﬁned as P < 0.05.
Simple regression analyses were performed and signiﬁcance of the cor-
relation was determined by the Pearson method.Fig. 2. MMP-2 content in the coronary eﬄuent. Panel A: Immuno-
blotting analysis for MMP-2 of coronary eﬄuents from I/R hearts
treated with saline (lane 1, 3 and 5) or HDL at 1 mg/ml (lane 2, 4 and
6). Panel B: Densitometric analysis of proMMP-2 (white bars) and
active MMP-2 (black bars) bands. ProMMP-2 was undetectable (n.d.)
in the coronary eﬄuent of HDL-treated hearts. Data are mean ± SEM,
n = 3 for each group. *P < 0.05 versus saline.3. Results
3.1. HDL attenuate cardiac MMP-2 activation and release
Gelatinolytic activities in homogenates of non-ischemic
(Control) hearts were detected by zymography at 75, 72 and
62 kDa (Fig. 1). The 72 kDa and the 62 kDa bands were iden-
tiﬁed as proMMP-2 and MMP-2, respectively. It is important
to note that in the SDS-containing gels, and diﬀerently from
the in vivo condition, both latent and active MMP-2 display
gelatinolytic activity. As expected, proMMP-2 represented
the major gelatinolytic activity in control hearts. I/R caused
an almost complete loss of both MMP-2 forms, as shown by
the clear-cut reduction of gelatinolytic activity in saline-treated
hearts (Fig. 1). In parallel, both pro- and active MMP-2 weredetected in the coronary eﬄuent collected during the ﬁrst
5 min of reperfusion (Fig. 2). Active MMP-2 was the predom-
inant form in the coronary eﬄuent, indicating that I/R actually
caused the activation and release of cardiac MMP-2. The deg-
radation of ﬁbronectin, one of the non-collagenous compo-
nents of ECM and substrate of MMP-2 [3], conﬁrmed that
MMP-2 is activated in ischemic hearts (Fig. 3).
Fig. 3. Eﬀect of HDL on ﬁbronectin degradation. Immunoblotting of
homogenates from non-ischemic hearts (Control, lane 2) and I/R
hearts treated with saline (lane 3) or with plasma-derived HDL (1 mg
of protein/ml, lane 4) immediately before ischemia. Puriﬁed ﬁbronectin
was also immunoblotted as control (FN, lane 1). Immunoblotting for
a-actin was used to conﬁrm the application of similar amount of
proteins to each lane. Representative of three separate experiments.
Fig. 4. Eﬀect of sHDL on cardiac MMP-2 content. Panel A:
Representative zymography of homogenates from non-ischemic hearts
(Control) and I/R hearts treated with saline, sHDL (0.5–2.0 mg of
protein/ml), or apoA-I (1 mg/ml) during the 10 min immediately before
ischemia. Panel B: Densitometric analysis of total MMP-2 gelatinolytic
activity in cardiac tissue samples. Data are expressed as mean ± SEM,
n = 3 for each group. *P < 0.05 versus saline.
Fig. 5. Eﬀect of HDL on cardiac MMP-2 expression. RT-PCR
analysis for MMP-2 and GAPDH of non-ischemic (Control) hearts
and I/R hearts treated with saline, HDL or LDL (both at 1 mg of
protein/ml). Representative of three separate experiments.
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dose-dependent way the I/R-induced loss of cardiac gelatino-
lytic activity, without aﬀecting the proMMP-2/active MMP-2
ratio (Fig. 1); at the maximum HDL dose, cardiac total gela-
tinolytic activity was 5.3 fold higher than in saline-treated I/
R hearts (Fig. 1). ProMMP-2 was undetectable in the coronary
eﬄuent of HDL-treated hearts and active MMP-2 was signif-
icantly lower than in coronary eﬄuent of saline-treated hearts
(P = 0.048) (Fig. 2), indicating that HDL prevented I/R-
nduced MMP-2 activation and release. Indeed, ﬁbronectin
degradation was signiﬁcantly attenuated in HDL-treated I/R
hearts (Fig. 3). The preservation of cardiac MMP-2 content
paralleled the HDL-induced prevention of postischemic car-
diac dysfunction and damage [6], as indicated by the signiﬁcant
correlation between total cardiac MMP-2 and post-ischemic
LVDP recovery (R = 0.953, P < 0.001), and CK release
(R =  0.954, P < 0.001). LDL, which do not possess cardio-
protective activity [6], did not preserve cardiac MMP-2 con-
tent, as demonstrated by the absence of gelatinolytic activity
in LDL-treated hearts (Fig. 1). sHDL made of apolipoprotein
A-I (apoA-I) and egg phosphatidylcholine also preserved car-
diac MMP-2 content (Fig. 4), which again correlated with
post-ischemic LVDP recovery (R = 0.998, P = 0.002) and CK
release (R =  0.985, P = 0.015) [7]. Lipid-free apoA-I had a
lower but signiﬁcant eﬀect on cardiac MMP-2 content
(Fig. 4). MMP-2 mRNA levels did not diﬀer among control,
saline-, HDL-, and LDL-treated hearts (Fig. 5), indicating that
the diﬀerences in cardiac MMP-2 content observed among the
various groups of hearts were not the result of changes in
MMP-2 gene expression.
3.2. HDL reduce cardiac LOOH levels
Radical oxygen species (ROS) can trigger the activation of
latent MMPs by oxidative modiﬁcation of the ‘‘cysteine
switch’’ [1,13]. To evaluate whether HDL inhibition of
MMP-2 activation and release was due to a reduction of
ROS levels, the concentrations of LOOH, the major initial
reaction products of lipid peroxidation, were measured in car-
diac tissues. If compared to non-ischemic control hearts, I/R
hearts treated with saline displayed a 4.3 fold increase ofLOOH levels (P < 0.001 vs controls) that was signiﬁcantly
reduced by the treatment with HDL: at the maximum dose
of HDL (1 mg/ml), cardiac LOOH concentration was reduced
by 58.6% (P < 0.001 vs saline-treated hearts) (Fig. 6). sHDL
also inhibited I/R-induced LOOH formation in a dose-depen-
dent way, with a 57.2% reduction at the highest dose (2 mg/ml)
(Fig. 6). The treatment with LDL did not signiﬁcantly aﬀect I/
R-induced LOOH formation, while lipid-free apoA-I caused a
small but not signiﬁcant decrease (Fig. 6).
Fig. 6. Eﬀect of HDL on cardiac LOOH production. LOOH content
was measured in non-ischemic hearts (Control) and in I/R hearts
treated with saline, HDL, LDL (1 mg/ml), sHDL or lipid-free apoA-I
(1 mg/ml) during the 10 min immediately before ischemia. Data are
mean ± SEM, n = 3 for each group. *P < 0.05 versus control;
#P < 0.05 versus saline.
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The present study demonstrates that both plasma-derived
and synthetic HDL attenuate the I/R-induced activation and
subsequent release of cardiac MMP-2. The prevention of
MMP-2 activation is dose-dependent, occurs at physiological
HDL concentrations, and is speciﬁc for HDL, as LDL had
no eﬀect. The preservation of the cardiac MMP-2 content by
HDL parallels the improvement of post-ischemic contractile
function and the reduction of cardiac damage, indicating that
prevention of MMP-2 activation represents a novel mechanism
for HDL-mediated cardioprotection.
MMP-2 is synthesized as a pro-enzyme, which is activated
extracellularly by proteolytic cleavage of the inhibitory pro-
peptide domain [1]. ROS also directly activate MMP-2 by oxi-
dizing the sulphydril bond between a cysteine residue of the
pro-domain and the Zn2+ catalytic center, resulting in partial
enzyme activation followed by an intramolecular cleavage of
the pro-peptide [1]. The I/R-induced ROS formation, which
occurs within the ﬁrst minutes of reperfusion [14], is likely
responsible for the rapid MMP-2 activation in I/R hearts
[15]. Active MMP-2 then contributes to early contractile dys-
function [5], through the degradation of intracellular proteins,
such as TnI [4], before being released from the heart. MMP
activation may also contribute to myocardial I/R injury in
humans, as demonstrated in patients undergoing coronary
bypass grafting with cardio-pulmonary bypass [16].
HDL are complex macromolecules with a number of activi-
ties in lipid transport and modulation of endothelial function.
In addition, HDL exert a variety of anti-oxidant eﬀects, which
may explain the inhibition of I/R-induced MMP-2 activation
observed in the present study. HDL were shown to reduce
ROS generation in a cell-free system [17], in cultured vascular
smooth muscle cells exposed to oxidized LDL [8], and in the
carotids of rabbits undergoing periarterial manipulation [18].
In the present study, the treatment with plasma-derived or syn-
thetic HDL signiﬁcantly reduced the I/R-induced ROS burst,
as demonstrated by the decrease of cardiac LOOH content,
fully consistent with a previous study in a similar experimental
setting [19]. This eﬀect may result either from inhibition of
ROS biosynthesis, by, e.g., chelation of transition metals
[20], or from enhanced ROS degradation, mediated by intra-cellular catalase [8], or HDL-carried paraoxonase [21]. Not
all these mechanisms are shared by sHDL and lipid-free
apoA-I, which certainly lack paraoxonase activity and do
not chelate transition metals [20], thus justifying the lower
activity vs. plasma-derived HDL in preventing hydroperoxide
formation and consequent MMP-2 activation.
The direct cardioprotection by HDL is thus the result of
multiple mechanisms, going from prevention of MMP-2 acti-
vation, to TNFa inactivation and stimulation of prostaglandin
release [6]. All together, these multiple mechanisms add to
other HDL functions in explaining the association of a low-
HDL phenotype with both short-term and long-term adverse
prognosis after an acute coronary event, and provide the ratio-
nale for the therapeutic use of HDL-derived products in a vari-
ety of cardiovascular diseases.References
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